Q1 2026 Divi's Laboratories Ltd Earnings Call Transcript
Key Points
- Divi's Laboratories Ltd (BOM:532488) maintained a robust and competitive position in the global market despite persistent pricing pressures, thanks to its strong backward integration model.
- The company is witnessing increased traction in its custom synthesis vertical, positioning itself as a preferred partner for global innovators seeking scalability and reliability.
- Significant strides have been made in expanding scientific and technological capabilities, including advanced platforms in flow chemistry, biocatalysis, and green chemistry.
- The newly commissioned solid-state peptide indices capacity has attracted strong interest from large companies, particularly those developing GLP-1 based treatments.
- Divi's Laboratories Ltd (BOM:532488) reported a consolidated total income of INR2,529 crores for Q1 FY 2026, up from INR2,197 crores in the corresponding quarter of the previous year.
- The generic business faced pricing pressures, which impacted gross margins, and additional costs such as logistical expenses and geopolitical issues also affected the business.
- The transition of several projects from R&D to commercial scale is expected to take 12 to 24 months, indicating potential delays in revenue realization.
- Despite backward integration efforts, the impact on gross margins is not yet fully realized, and the company continues to face challenges in maintaining supply consistency.
- The peptide capacity, although attracting interest, requires time for qualifications, customer approvals, and regulatory clearances before commercial supplies can begin.
- Geopolitical uncertainties and shifts in global supply chains continue to pose challenges, impacting the broader macro environment and potentially affecting future operations.
Ladies and gentlemen, good day, and welcome to the earnings conference call of Divi's Laboratories Limited for Q1 FY 2026 (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. M. Satish Choudhury. Over to you, sir.
'- -
Good afternoon to all of you. I'm M. Satish Choudhury, Company Secretary and Chief Investor Relations Officer of Divi's Laboratories Limited. I welcome you all to the earnings call of the company for the quarter ended 30th June 2025. From Divi's Labs, we have with us today Dr. Kiran S. Divi, Whole-Time Director and Chief Executive Officer; Mr. Nilima Prasad Divi, Whole-Time Director, Commercial; and Mr. Venkatesa Perumallu Pasumarthi, Chief Financial Officer.
During the day, our Board has approved unaudited financial results for the quarter ended June 30, 2025 and we have released the same to the stock exchanges as well as updated the same in our website.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
